RA Capital Management L.P. Sells 1,380,605 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

RA Capital Management L.P. cut its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 11.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,229,099 shares of the company's stock after selling 1,380,605 shares during the quarter. RA Capital Management L.P. owned about 16.39% of Fulcrum Therapeutics worth $36,518,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. National Bank of Canada FI lifted its holdings in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company's stock worth $28,000 after buying an additional 4,000 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Fulcrum Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company's stock worth $43,000 after acquiring an additional 4,701 shares during the period. Walleye Capital LLC purchased a new stake in Fulcrum Therapeutics in the 3rd quarter worth approximately $59,000. Intech Investment Management LLC bought a new position in Fulcrum Therapeutics in the 3rd quarter valued at $62,000. Finally, Profund Advisors LLC purchased a new position in shares of Fulcrum Therapeutics during the 2nd quarter valued at $68,000. Hedge funds and other institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Price Performance

Fulcrum Therapeutics stock traded up $0.25 during mid-day trading on Thursday, hitting $3.76. The company's stock had a trading volume of 814,697 shares, compared to its average volume of 983,611. The business has a 50 day moving average price of $3.47 and a 200-day moving average price of $6.10. Fulcrum Therapeutics, Inc. has a 12 month low of $2.86 and a 12 month high of $13.70. The stock has a market cap of $202.81 million, a price-to-earnings ratio of -12.13 and a beta of 2.14.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on FULC shares. Cantor Fitzgerald lowered Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Thursday, September 12th. Royal Bank of Canada reiterated a "sector perform" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Leerink Partnrs cut shares of Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, September 12th. HC Wainwright reiterated a "neutral" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. Finally, Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a "buy" rating to a "hold" rating and decreased their price target for the stock from $22.00 to $3.00 in a report on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $9.33.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.